ABBV vs AMGN

Key Takeaways

• AbbVie has successfully navigated the Humira patent cliff, with immunology blockbusters Skyrizi and Rinvoq now annualizing at more than $26 billion combined and driving robust top-line growth.
• Amgen delivered 10% revenue growth in full-year 2025, with 14 products exceeding $1 billion in annual sales and a diversified portfolio spanning oncology, cardiovascular disease, rare disease, and inflammation.
• Both companies face loss-of-exclusivity headwinds — AbbVie with continued Humira erosion and Amgen with upcoming biosimilar competition for Prolia and Xgeva — but each has distinct strategies to offset those declines.
• AbbVie offers a significantly higher dividend yield at approximately 2.72% with a 5.5% recent increase, while Amgen carries a lower yield but has raised its dividend for 14 consecutive years.
• Amgen's obesity candidate MariTide represents a potential high-upside catalyst, whereas AbbVie's pipeline breadth across immunology, neuroscience, and oncology offers a more diversified long-term growth pathway.
• From a valuation standpoint, both stocks trade at reasonable forward price-to-earnings multiples relative to the large-cap biopharma peer group, though AbbVie's larger market capitalization of roughly $450 billion reflects its revenue scale advantage.

Introduction

In the large-cap biopharmaceutical universe, few comparisons capture investor attention quite like ABBV versus AMGN. AbbVie and Amgen are two of the world's most established drug developers, each with deep pipelines, blockbuster product portfolios, and decades of experience navigating the complex dynamics of drug pricing, patent expirations, and regulatory evolution. For traders and long-term investors alike, understanding how these two giants stack up across growth trajectories, risk profiles, and market positioning is essential. This stock comparison examines both companies through the lens of recent financial performance, pipeline catalysts, and shifting market sentiment — offering a data-driven look at which name may hold an edge in the current environment.

ABBV Overview and Recent Performance

AbbVie, headquartered in North Chicago, Illinois, has solidified its reputation as an immunology powerhouse. The company's flagship next-generation drugs — Skyrizi (risankizumab) and Rinvoq (upadacitinib) — have more than compensated for the widely anticipated decline of Humira, which lost U.S. patent exclusivity in 2023. In the third quarter of 2025, AbbVie reported worldwide net revenues of $15.78 billion, a 9.1% year-over-year increase on a reported basis, while Skyrizi alone generated $4.71 billion in quarterly sales. For the full year 2025, AbbVie delivered total net revenues of approximately $61.2 billion, exceeding initial expectations by more than $2 billion and marking an all-time high for the company.

In recent weeks, AbbVie's share price has shown notable strength, trading near the upper end of its 52-week range and posting a one-year total return of approximately 37%. The company's neuroscience portfolio — anchored by Vraylar, Botox Therapeutic, and newer migraine therapies Ubrelvy and Qulipta — grew more than 20% in the third quarter, adding a second powerful growth engine. However, headwinds persist: Humira sales continue to decline at a pace exceeding 50% year over year, and the aesthetics segment, which includes Botox Cosmetic and Juvederm, has faced persistent softness due to macroeconomic pressures on consumer discretionary spending. AbbVie's aggressive acquisition strategy — including the purchases of Capstan Therapeutics and Gilgamesh Pharmaceuticals' bretisilocin — underscores management's commitment to replenishing the pipeline, though these deals have weighed on near-term GAAP (Generally Accepted Accounting Principles) earnings through elevated acquired IPR&D (in-process research and development) charges.

AMGN Overview and Recent Performance

Amgen, based in Thousand Oaks, California, stands as one of the original biotechnology pioneers, with a portfolio that today spans oncology, cardiovascular disease, bone health, inflammation, and rare disease. The company's 2024 acquisition of Horizon Therapeutics added key rare disease assets — including Tepezza, Krystexxa, and Uplizna — that have meaningfully diversified its revenue base. In full-year 2025, Amgen reported total revenues of $36.8 billion, representing 10% year-over-year growth, with 18 products achieving record sales and 14 surpassing the $1 billion annual threshold. Non-GAAP (non-Generally Accepted Accounting Principles) earnings per share reached $21.84, a 10% increase from the prior year.

Amgen's stock has performed strongly, gaining approximately 26% in 2025 and outperforming the broader S&P 500 index. Key growth drivers include Repatha, which grew 36% year over year to surpass $3 billion in annual sales, and Tezspire, which surged 52% to nearly $1.5 billion. The company's biosimilar portfolio has also become a significant contributor, generating roughly $3 billion in 2025 sales — a 37% increase — with launches of Wezlana (a Stelara biosimilar) and Pavblu (an Eylea biosimilar) gaining traction. Yet Amgen faces meaningful challenges: Prolia and Xgeva patents expired in early 2025, and biosimilar competition is expected to accelerate erosion in 2026. Additionally, the Inflation Reduction Act has introduced pricing pressure on select products, with Otezla selected for Medicare price setting beginning in 2027 and an associated $1.2 billion intangible asset impairment charge recorded in 2025. The company's obesity candidate MariTide remains a focal point for investor sentiment, with Phase 3 data readouts representing a potential catalyst.

Trending AI Robots

In a market environment where speed and data-driven decision-making increasingly separate top performers from the rest, Tickeron's Trending AI Robots page offers traders and investors a curated selection of the platform's most effective AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers — including ABBV and AMGN — but only those demonstrating the strongest alignment with current market conditions earn a place in the Trending AI Robots section. These bots employ diverse trading styles, from swing trading and momentum strategies to longer-term trend-following approaches, with performance statistics, win rates, and trade frequency varying across bots. Some bots have demonstrated annualized returns that meaningfully outperform benchmark indices, though past performance does not guarantee future results. For investors seeking to complement their own analysis with algorithmic insight, exploring the curated Trending AI Robots may offer a practical starting point — visit the Trending AI Robots page to explore the current selection.

Head-to-Head Comparison

When comparing ABBV and AMGN side by side, several structural differences and trade-offs emerge. On revenue scale, AbbVie holds a clear advantage — its $61 billion top line substantially exceeds Amgen's $37 billion, and AbbVie's market capitalization of approximately $450 billion is more than double Amgen's $186 billion. This scale is concentrated, however: AbbVie's immunology franchise, led by Skyrizi and Rinvoq, accounts for roughly half of total revenue, creating a degree of therapeutic-area concentration risk. Amgen's revenue base, by contrast, is spread across a broader set of therapeutic categories and includes a growing biosimilar segment that provides a differentiated growth vector.

On the patent cliff front, both companies face exposure but with different timelines. AbbVie is already deep into the Humira erosion cycle and has demonstrated that its newer immunology drugs can absorb the decline — a dynamic that has bolstered investor confidence in recent quarters. Amgen, meanwhile, is entering its patent expiration headwind phase with Prolia and Xgeva, introducing near-term uncertainty around the pace of volume erosion. In terms of pipeline catalysts, Amgen's MariTide obesity program offers a binary but potentially transformative opportunity in the GLP-1 (glucagon-like peptide-1) receptor agonist space, where the total addressable market is enormous. AbbVie's pipeline is less concentrated around a single high-stakes asset and instead features numerous late-stage programs — including tavapadon for Parkinson's disease and multiple Rinvoq indication expansions — that collectively broaden its medium-term growth runway.

Dividend investors may find AbbVie's profile more appealing: its forward dividend yield of approximately 2.72% is meaningfully higher than Amgen's, and the company has increased its dividend by more than 330% since inception in 2013. Amgen's dividend track record is also strong — 14 consecutive years of increases — but the yield itself is comparatively modest. On the risk side, AbbVie's beta of 0.28 indicates significantly lower volatility than the broader market, which may appeal to more conservative positioning, while Amgen's more diversified biosimilar and rare disease exposure introduces distinct risk-return dynamics tied to competitive entry and pricing policy changes.

Tickeron AI Verdict

Based on observable trend consistency, relative momentum, and the balance of near-term catalysts versus headwinds, Tickeron's AI-driven analytical framework would likely tilt in favor of ABBV in the current market environment. AbbVie's demonstrated ability to grow revenues at a mid-to-high single-digit pace despite losing exclusivity on the largest drug in pharmaceutical history reflects a rare degree of execution and portfolio resilience. The company's strong free cash flow generation, growing dividend, and broad pipeline — particularly the expanding label opportunity for Rinvoq and the upcoming regulatory decision on tavapadon — provide multiple layers of fundamental support. Its exceptionally low beta further suggests that trend-following and stability-oriented algorithms would find the stock's recent price structure constructive.

That said, Amgen is by no means a weak counterpart. Its MariTide obesity program, robust biosimilar franchise, and the rare disease portfolio acquired from Horizon Therapeutics offer legitimate upside catalysts that could shift algorithmic preference if clinical data or commercial execution exceed expectations. The AI verdict is probabilistic, not definitive: both stocks exhibit qualities that could attract different types of trading bots depending on strategy, timeframe, and risk tolerance. In a head-to-head relative comparison under current observable conditions, however, AbbVie's smoother trend profile, more mature post-patent-cliff earnings trajectory, and lower volatility characteristics appear better aligned with the stability and consistency metrics that Tickeron's models tend to prioritize.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations